Filed pursuant to Rule 424(b)(5)
Registration No. 333-260758
Supplement No. 3 dated May 3, 2024
To Prospectus Supplement dated November 4, 2021
as supplemented by Supplement No 1., dated February 25, 2022
as supplemented further by Supplement No 2., dated November 3, 2023
(To Prospectus dated November 4, 2021)
$400,000,000
![LOGO](https://capedge.com/proxy/424B5/0001193125-24-130674/g803343g05v13.jpg)
Watsco, Inc.
Common stock
This supplement no. 3, referred to as this Supplement, supplements certain information contained in the prospectus supplement dated November 4, 2021, as supplemented by supplement no. 1 dated February 25, 2022 and supplement no 2. dated November 3, 2023, collectively, and as amended by this Supplement, referred to as the prospectus supplement, relating to the issuance and sale of shares of our Common stock, par value $0.50 per share, referred to as the Common stock, from time to time through Robert W. Baird & Co. Incorporated, referred to as Baird, acting as agent or principal, in negotiated transactions or transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, referred to as the Securities Act, including sales made directly on the New York Stock Exchange, or the NYSE, or sales made to or through a market maker other than on an exchange. This Supplement should be read in conjunction with the prospectus supplement and the prospectus dated November 4, 2021 to which the prospectus supplement relates. Capitalized terms used in this Supplement and not defined herein have the respective meanings ascribed to such terms in the prospectus supplement. This Supplement amends and restates only those sections of the prospectus supplement contained in this Supplement; all other sections of the prospectus supplement remain unchanged. For clarity, references to “the prospectus supplement” or “this prospectus supplement” refer to the prospectus supplement as amended by this Supplement.
This Supplement relates to our having entered into the third amended and restated sales agreement, dated as of May 3, 2024, between us and Baird, which we refer to as the third amended and restated sales agreement, pursuant to which we may issue and sell up to $400,000,000 of Common stock through Baird, as described above. Prior to our entry into the third amended and restated sales agreement, we had been able to issue and sell up to $300,000,000 of Common stock through Baird pursuant to the second amended and restated sales agreement, dated as of November 3, 2023, between us and Baird, which we refer to as the second amended and restated sales agreement, and, as of the date of this Supplement, we had sold 757,000 shares of our Common stock under the prospectus supplement and the accompanying prospectus for an aggregate gross sales price of $298,455,276. In accordance with the third amended and restated sales agreement, shares of Common stock having an aggregate gross sales price of up to an additional $400,000,000 currently remain available for sale under such agreement, the prospectus supplement and the accompanying prospectus.
Our Common stock is listed on the New York Stock Exchange under the ticker symbol “WSO.” On May 2, 2024, the last reported sale price for our Common stock was $456.08 per share.
Investing in our securities involves risks. See “Risk Factors” beginning on page S-3 of this prospectus supplement.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS SUPPLEMENT, THE PROSPECTUS SUPPLEMENT OR THE ACCOMPANYING PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
Baird
The date of this Supplement is May 3, 2024.